文献速递肝病

丙型肝炎病毒感染所致失代偿期肝硬化患者直接抗病毒治疗后肝功能改善的基线相关因素

Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection.
PubMed 文献 · Gastroenterology · 2018-03-11

腹水、脑病、白蛋白<3.5 g/dL、丙氨酸氨基转移酶<60 U/L及体重指数>25 kg/m2与未降至Child-Pugh-Turcotte A级风险增加相关。基于5项基线因素建立BE3A评分,评分4-5分者降至A级的风险比为52.3(95%CI 15.2-179.7),可作为共同决策工具。

要点

  • 腹水、脑病、白蛋白<3.5 g/dL、丙氨酸氨基转移酶<60 U/L及体重指数>25 kg/m2与未降至Child-Pugh-Turcotte A级风险增加独立相关。
  • 白蛋白<2.8 g/dL及胆红素异常与肝移植或死亡风险增加相关。
  • BE3A评分4-5分者降至Child-Pugh-Turcotte A级的风险比为52.3(95%CI 15.2-179.7)。

核心结论

  • 5项基线因素(体重指数、脑病、腹水、丙氨酸氨基转移酶及白蛋白血清水平)与丙型肝炎病毒相关失代偿期肝硬化患者接受直接抗病毒治疗后Child-Pugh-Turcotte评分降至A级相关。
  • 基于上述因素建立的BE3A评分可作为共同决策工具,量化直接抗病毒治疗对失代偿期肝硬化患者的潜在获益。

研究设计与样本

  • 回顾性分析4项关于索磷布韦为基础方案治疗丙型肝炎病毒相关失代偿期肝硬化患者的试验数据。
  • 共纳入502例Child-Pugh-Turcotte B级和120例C级患者。
  • 治疗方案包括:来迪派韦、索磷布韦联合利巴韦林或维帕他韦、索磷布韦联合利巴韦林治疗12或24周;或索磷布韦联合利巴韦林治疗48周。
  • 收集人口学、临床、治疗应答及实验室数据,分析其与患者36周结局的相关性。

主要发现

  • 腹水或脑病、白蛋白<3.5 g/dL或丙氨酸氨基转移酶<60 U/L、体重指数>25 kg/m2与未降至Child-Pugh-Turcotte A级风险增加相关,且独立于持续病毒学应答。
  • 白蛋白<2.8 g/dL及胆红素水平异常与肝移植或死亡风险增加相关。
  • 基于5项基线因素(体重指数、脑病、腹水、丙氨酸氨基转移酶及白蛋白血清水平)建立BE3A评分,这些因素与患者结局显著相关。
  • BE3A评分4-5分患者降至Child-Pugh-Turcotte A级的风险比为52.3(95%CI 15.2-179.7)。

关键数值与推荐

  • 未降至Child-Pugh-Turcotte A级风险增加的相关因素:腹水或脑病、白蛋白<3.5 g/dL或丙氨酸氨基转移酶<60 U/L、体重指数>25 kg/m2。
  • 肝移植或死亡风险增加的相关因素:白蛋白<2.8 g/dL、胆红素水平异常。
  • BE3A评分4-5分患者降至Child-Pugh-Turcotte A级的风险比为52.3(95%CI 15.2-179.7)。

临床怎么用

  • BE3A评分可作为共同决策工具,量化直接抗病毒治疗对失代偿期肝硬化患者的潜在获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Treatment with direct-acting antiviral (DAA) agents can reduce Model for End-Stage Liver Disease and Child-Pugh-Turcotte (CPT) scores in patients with decompensated cirrhosis caused by hepatitis C virus. However, many of these patients still die or require liver transplantation. We collected data on baseline features of patients and aimed to develop a scoring system to predict response to DAA therapy. METHODS: We performed a retrospective analysis of data from 4 trials on the effects of sofosbuvir-based therapy in patients with hepatitis C virus-associated decompensated cirrhosis (502 of CPT class B and 120 of CPT class C). In these trials, patients were given 12 or 24 weeks of treatment with ledipasvir, sofosbuvir, and ribavirin or velpatasvir, sofosbuvir, and/or ribavirin, or 48 weeks of treatment with sofosbuvir and ribavirin. We collected demographic, clinical, treatment response, and laboratory data from patients and tested their associations with patient outcomes at 36 weeks. The primary outcome was factors associated with reduction of CPT score to class A. RESULTS: The presence of ascites or encephalopathy, serum level of albumin <3.5 g/dL or alanine aminotransferase <60 U/L, and body mass index >25 kg/m2 were associated with an increased risk of not achieving a reduction in CPT to class A, independent of sustained viral response to therapy. Serum level of albumin <2.8 g/dL and abnormal level of bilirubin were associated with an increased risk of liver transplantation or death. We developed a scoring system based on 5 baseline factors (body mass index, encephalopathy, ascites, and serum levels of alanine aminotransferase and albumin) associated significantly with patient outcomes, which we called the "BE3A score." For patients with scores of 4-5, the hazard ratio for reduction of CPT score to class A was 52.3 (95% confidence interval, 15.2-179.7). CONCLUSIONS: We identified 5 baseline factors (body mass index, encephalopathy, ascites, and serum levels of alanine aminotransferase and albumin) associated with a reduction of CPT score to class A in patients with hepatitis C virus-associated decompensated cirrhosis receiving DAA therapy. We developed a predictive score using these factors, called the BE3A score, which can be used as a shared decision-making tool, quantifying the potential benefits of DAA therapy for patients with decompensated cirrhosis.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. El-Sherif O, Jiang ZG, Tapper EB, et al. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. Gastroenterology. 2018. PMID: 29535028. doi:10.1053/j.gastro.2018.03.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。